• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rifaximin Does Not Increase the Rate of 30-Day Mortality in Patients With Cirrhosis and Daptomycin in Two National US-Based Cohorts.

作者信息

Silvey Scott, Patel Nilang, Khoruts Alexander, Bajaj Jasmohan S

机构信息

Department of Biostatistics, Virginia Commonwealth University, Richmond, Virginia.

Department of Medicine, Virginia Commonwealth University, Richmond, Virginia.

出版信息

Gastroenterology. 2025 Aug;169(2):349-351.e3. doi: 10.1053/j.gastro.2025.03.014. Epub 2025 Mar 21.

DOI:10.1053/j.gastro.2025.03.014
PMID:40122471
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12289421/
Abstract
摘要

相似文献

1
Rifaximin Does Not Increase the Rate of 30-Day Mortality in Patients With Cirrhosis and Daptomycin in Two National US-Based Cohorts.在美国两个全国性队列研究中，利福昔明不会增加肝硬化患者和达托霉素患者30天死亡率。
Gastroenterology. 2025 Aug;169(2):349-351.e3. doi: 10.1053/j.gastro.2025.03.014. Epub 2025 Mar 21.
2
Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.利福昔明预防和治疗肝硬化患者肝性脑病。
Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD011585. doi: 10.1002/14651858.CD011585.pub2.
3
Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled trial.利福昔明对重症肝硬化腹水患者的影响：一项随机双盲安慰剂对照试验。
J Hepatol. 2025 Jul 11. doi: 10.1016/j.jhep.2025.06.019.
4
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis.抗生素预防肝硬化患者自发性细菌性腹膜炎：一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 16;1(1):CD013125. doi: 10.1002/14651858.CD013125.pub2.
5
Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis.利福昔明在不同应用剂量和策略下对肝性脑病的预防和治疗作用：网络荟萃分析。
BMC Gastroenterol. 2024 Mar 4;24(1):94. doi: 10.1186/s12876-024-03184-0.
6
Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis.系统评价与荟萃分析：利福昔明预防自发性细菌性腹膜炎
Aliment Pharmacol Ther. 2017 Dec;46(11-12):1029-1036. doi: 10.1111/apt.14361. Epub 2017 Oct 9.
7
Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis.利福昔明预防肝硬化患者自发性细菌性腹膜炎和肝肾综合征：一项系统评价和荟萃分析。
Eur J Gastroenterol Hepatol. 2017 Oct;29(10):1109-1117. doi: 10.1097/MEG.0000000000000940.
8
Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial.微生物群移植治疗肝硬化肝性脑病：THEMATIC试验。
J Hepatol. 2025 Jan 10. doi: 10.1016/j.jhep.2024.12.047.
9
Evaluating Clinical Outcomes of Adjunct Rifaximin Therapy in Patients with Overt Hepatic Encephalopathy: A Prospective Randomized Study.评估利福昔明辅助治疗显性肝性脑病患者的临床结局：一项前瞻性随机研究。
Euroasian J Hepatogastroenterol. 2025 Jan-Jun;15(1):58-62. doi: 10.5005/jp-journals-10018-1473. Epub 2025 Jun 18.
10
The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis.利福昔明治疗肠易激综合征的疗效和安全性：系统评价和荟萃分析。
Am J Gastroenterol. 2012 Jan;107(1):28-35; quiz 36. doi: 10.1038/ajg.2011.355. Epub 2011 Nov 1.

本文引用的文献

1
Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.利福昔明-α可减少肝硬化和肝性脑病中的肠道来源的炎症和粘蛋白降解：RIFSYS 随机对照试验。
J Hepatol. 2022 Feb;76(2):332-342. doi: 10.1016/j.jhep.2021.09.010. Epub 2021 Sep 24.
2
The Evolving Challenge of Infections in Cirrhosis.肝硬化中感染问题的不断演变的挑战
N Engl J Med. 2021 Jun 17;384(24):2317-2330. doi: 10.1056/NEJMra2021808.
3
Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis.肝硬化患者肠道微生物组中抗生素耐药基因的影响。
Gastroenterology. 2021 Aug;161(2):508-521.e7. doi: 10.1053/j.gastro.2021.04.013. Epub 2021 Apr 20.
4
Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list.利福昔明可降低肝移植等待名单患者自发性细菌性腹膜炎、静脉曲张出血和全因入院的发生率。
Aliment Pharmacol Ther. 2019 Aug;50(4):435-441. doi: 10.1111/apt.15326. Epub 2019 Jun 6.
5
Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.利福昔明重复治疗肠易激综合征：粪便微生物对抗生素的敏感性无临床显著变化。
Dig Dis Sci. 2017 Sep;62(9):2455-2463. doi: 10.1007/s10620-017-4598-7. Epub 2017 Jun 6.
6
In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth.利福昔明对小肠细菌过度生长患者分离株的体外活性。
Int J Antimicrob Agents. 2014 Mar;43(3):236-41. doi: 10.1016/j.ijantimicag.2013.12.008. Epub 2014 Jan 6.
7
Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.利福昔明对肝硬化伴轻微肝性脑病患者代谢组的调节作用。
PLoS One. 2013;8(4):e60042. doi: 10.1371/journal.pone.0060042. Epub 2013 Apr 2.
8
Rifaximin treatment in hepatic encephalopathy.利福昔明治疗肝性脑病。
N Engl J Med. 2010 Mar 25;362(12):1071-81. doi: 10.1056/NEJMoa0907893.